Share ownership Subgen AI AB

SUBGEN

SE0026820854

Advanced Medical Equipment & Technology

End-of-day quote Nasdaq Stockholm Other stock markets 2026-03-10			5-day change	1st Jan Change
0.2560 ^SEK	-7.91%		-18.47%	-73.53%

Mar. 04	Subgen AI to Launch Voluntary Share Offer for Substrate AI Shareholders	MT
Mar. 04	Subgen AI Seeks to Increase Stake in Spanish Subsidiary Substrate AI	FW

Share class: Subgen AI AB

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	49,248,535	28,180,538 ( 57.22 %)	0	57.22 %

Major shareholders: Subgen AI AB

Name	Equities	%	Valuation
FCG Fonder AB 0.000491 %	13	0.000491 %	0 kr

Breakdown by shareholder type

Unknown

100%

Based on 1000 largest holdings

Geographical origin of shareholders

Based on 1000 largest holdings

Magnasense AB, formerly AegirBio AB is a Sweden-based medicine company focused therapeutic drug monitoring of biologic therapies in the autoimmune, oncology and neurology space. The Company offers tests to monitor and optimize the dosage of biological drugs via its patented technology platform. It aims to provide personalized treatment by tracking drugs levels in individuals. Magnasense AB combines core technologies from LifeAssays and Abreos Biosciences. LifeAssays is a diagnostics company based in Sweden, which owns the Magnia Point of Care and Point of Need reader technology. Abreos Biosciences is a California-based biotech, which is a developer of the Veritope chemistry platform for detecting levels of biologic drugs in patient samples.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company